Avenue Therapeutics, Inc. (ATXI) |
| 0.7101 0 (0%) 10-10 13:21 |
| Open: | 0.7101 |
| High: | 0.7101 |
| Low: | 0.7101 |
| Volume: | 1,127 |
| Market Cap: | 2(M) |
| PE Ratio: | 0.28 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.94 |
| Resistance 1: | 0.78 |
| Pivot price: | 0.76 |
| Support 1: | 0.52 |
| Support 2: | 0.44 |
| 52w High: | 2.7 |
| 52w Low: | 0.1653 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Financials
| EPS | 2.580 |
| Book Value | 1.270 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.440 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 21.15 |
| Return on Assets (ttm) | -86.9 |
| Return on Equity (ttm) | -185.5 |
Company news
Mon, 31 Mar 2025
Avenue Therapeutics Inc. (ATXI) reports earnings - qz.com
Fri, 07 Mar 2025
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com
Fri, 29 Nov 2024
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Thu, 14 Nov 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Wed, 17 Jul 2024
Avenue Therapeutics To Release Kennedy's Disease Trial Findings Mid-Year - RTTNews
Wed, 29 Nov 2023
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today? - InvestorPlace
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
